~~<i id='274C4E2309'><strike id='274C4E2309'><tt id='274C4E2309'><pre id='274C4E2309'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：entertainment 2025-09-28 04:05:20 Page View：97729

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How AI can help patients find reliable information about doctors
Next article： Medical records are filled with copy

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Lack of health data on LGBTQ+ people has serious consequences

FrankFranklinII/APLackofhealthdataonLGBTQ+peoplehasreal-worldconsequences.Aparticipantina2020reportf

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

UnitedHealth, Optum discontinue NaviHealth name

MarkLennihan/APUnitedHealthGroupandOptumaregettingridofthenameoftheirtech-drivencaremanagementcompan